Literature DB >> 16140928

JunB induced by constitutive CD30-extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase signaling activates the CD30 promoter in anaplastic large cell lymphoma and reed-sternberg cells of Hodgkin lymphoma.

Mariko Watanabe1, Masataka Sasaki, Kinji Itoh, Masaaki Higashihara, Kazuo Umezawa, Marshall E Kadin, Lawrence J Abraham, Toshiki Watanabe, Ryouichi Horie.   

Abstract

High expression of CD30 and JunB is characteristic of tumor cells in anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma (HL). Possible interactions of CD30 and JunB were examined in this study. We found that the CD30 promoter in tumor cells of both nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK)-positive and NPM-ALK-negative ALCL and HL is regulated by a constitutively active CD30-extracellular signal-regulated kinase (ERK) 1/2 mitogen-activated protein kinase (MAPK). Phosphorylation of ERK1/2 MAPK was confirmed in nuclei of tumor cells in both ALCL and HL. CD30-ERK1/2 MAPK signals induce JunB expression, which maintains high activity of the CD30 promoter. JunB induction seems to be largely independent of nuclear factor kappaB in ALCL and HL. These results show a common mechanism of CD30 overexpression in ALCL and HL, although the outcome of CD30 signaling differs between NPM-ALK-positive ALCL and NPM-ALK-negative ALCL, cutaneous ALCL, and HL as we recently reported.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140928     DOI: 10.1158/0008-5472.CAN-05-0925

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  41 in total

1.  Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes.

Authors:  Roberto Piva; Elisa Pellegrino; Michela Mattioli; Luca Agnelli; Luigia Lombardi; Francesco Boccalatte; Giulia Costa; Bruce A Ruggeri; Mangeng Cheng; Roberto Chiarle; Giorgio Palestro; Antonino Neri; Giorgio Inghirami
Journal:  J Clin Invest       Date:  2006-11-16       Impact factor: 14.808

2.  Evaluation of enrichment techniques for mass spectrometry: identification of tyrosine phosphoproteins in cancer cells.

Authors:  Jonathan A Schumacher; David K Crockett; Kojo S J Elenitoba-Johnson; Megan S Lim
Journal:  J Mol Diagn       Date:  2007-04       Impact factor: 5.568

Review 3.  Pathobiology of ALK+ anaplastic large-cell lymphoma.

Authors:  Hesham M Amin; Raymond Lai
Journal:  Blood       Date:  2007-05-22       Impact factor: 22.113

4.  Human CD30+ B cells represent a unique subset related to Hodgkin lymphoma cells.

Authors:  Marc A Weniger; Enrico Tiacci; Stefanie Schneider; Judith Arnolds; Sabrina Rüschenbaum; Janine Duppach; Marc Seifert; Claudia Döring; Martin-Leo Hansmann; Ralf Küppers
Journal:  J Clin Invest       Date:  2018-06-11       Impact factor: 14.808

5.  JunB breakdown in mid-/late G2 is required for down-regulation of cyclin A2 levels and proper mitosis.

Authors:  Rosa Farràs; Véronique Baldin; Sandra Gallach; Claire Acquaviva; Guillaume Bossis; Isabelle Jariel-Encontre; Marc Piechaczyk
Journal:  Mol Cell Biol       Date:  2008-04-07       Impact factor: 4.272

Review 6.  Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects.

Authors:  Naoko Tsuyama; Kana Sakamoto; Seiji Sakata; Akito Dobashi; Kengo Takeuchi
Journal:  J Clin Exp Hematop       Date:  2017

7.  The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment.

Authors:  F Fan; M H Bashari; E Morelli; G Tonon; S Malvestiti; S Vallet; M Jarahian; A Seckinger; D Hose; L Bakiri; C Sun; Y Hu; C R Ball; H Glimm; M Sattler; H Goldschmidt; E F Wagner; P Tassone; D Jaeger; K Podar
Journal:  Leukemia       Date:  2016-11-28       Impact factor: 11.528

Review 8.  Expression patterns of the activator protein-1 (AP-1) family members in lymphoid neoplasms.

Authors:  Alexandra Papoudou-Bai; Eleftheria Hatzimichael; Alexandra Barbouti; Panagiotis Kanavaros
Journal:  Clin Exp Med       Date:  2016-09-06       Impact factor: 3.984

Review 9.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

10.  Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126.

Authors:  M Ito; N Zhao; Z Zeng; C C Chang; Y Zu
Journal:  Cancer Gene Ther       Date:  2010-05-07       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.